$40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting pathological senescent cells via ferroptosis. Novel senolytic mechanism.
Rubedo Life Sciences is a senolytic drug company that has advanced RLS-1496 into Phase 1 clinical trials — the first GPX4 (glutathione peroxidase 4) modulator designed to selectively eliminate pathological senescent cells through ferroptosis, a form of programmed cell death. The company has raised $40 million in Series A financing and dosed its first patient in June 2025, with a systemic formulation entering Phase 1 planned for 2026 that would dramatically broaden its clinical scope.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.